View ValuationInventiva 将来の成長Future 基準チェック /36Inventiva利益と収益がそれぞれ年間56.1%と51.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に33.8% 40.1%なると予測されています。主要情報56.1%収益成長率40.08%EPS成長率Biotechs 収益成長23.7%収益成長率51.3%将来の株主資本利益率33.81%アナリストカバレッジGood最終更新日10 Jul 2026今後の成長に関する最新情報Breakeven Date Change • Oct 29No longer forecast to breakevenThe 7 analysts covering Inventiva no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.7m in 2027. New consensus forecast suggests the company will make a loss of €23.8m in 2027.Breakeven Date Change • Oct 01Forecast to breakeven in 2027The 8 analysts covering Inventiva expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2026. The company is expected to make a profit of €15.7m in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Jun 04Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 27,272,727 Price\Range: $4.4 Discount Per Security: $0.264お知らせ • Jun 03Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners LimitedInventiva S.A. entered into an agreement with funds and accounts managed by new investors BlackRock, Inc., and Claret Capital Partners Limited on June 1, 2026. The company will issue a first tranche for a maximum amount of €35 million consisting of senior secured convertible bonds, convertible into new ordinary shares, subject to satisfaction of certain closing conditions; a second tranche for a maximum amount of €40 million consisting of senior secured amortized bonds, subject to satisfaction of certain closing conditions; and a third tranche for a maximum amount of €55 million consisting of senior secured amortized bonds, available for the company to draw at its election until February 15, 2027. The company also has an optional additional tranche for a maximum amount of €20 million, subject to mutual consent, following the approval of the NDA for NATiV3. Pursuant to the terms of the subscription agreement, the lenders will receive warrants exercisable for up to €6.75 million worth of ordinary shares (or up to €12.35 million in the event of a shortfall event, as described below), expected to be granted concurrently with the drawdown of tranches A and B €2.75 million worth of ordinary shares are expected to be granted concurrently with the drawdown of tranche C.お知らせ • May 26Inventiva S.A., Annual General Meeting, Jun 30, 2026Inventiva S.A., Annual General Meeting, Jun 30, 2026. Location: hotel villa m 24 30 boulevard pasteur, paris Franceお知らせ • Apr 25Inventiva Announces Executives ChangesInventiva announced new members of its leadership team: Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These recruitments strengthen Inventiva’s leadership team as the Company prepares for the top-line data readout from the NATiV3 Phase 3 trial evaluating lanifibranor, expected in the fourth quarter of 2026. The new team members bring robust financial management, strong legal and governance oversight, and organizational expertise in building high-performing teams, positioning Inventiva to navigate its next phase of growth with confidence and discipline. Jean Volatier and Nathalie Harroy, who have respectively served as Chief Financial Officer and Head of Human Resources and have been with Inventiva since its inception, have played a key role in the Company’s development over the years and bring deep institutional knowledge. Jean Volatier will transition to the role of EVP Finance & Corporate Social Responsibility, where he will continue to support the Company on key strategic priorities. Nathalie Harroy will also remain with Inventiva, continuing to contribute her experience and expertise to the organization. The Company is pleased that both will remain part of Inventiva and continue to support its next phase of growth. Coles comes to Inventiva from Vivet Therapeutics, where she was head of Legal and Finance involved in all strategic and operational aspects of the business from the creation of the company through negotiations of an option to purchase deal with Pfizer. She previously was general counsel at Inventiva from 2012-2014 and again from 2019-2021, during its Nasdaq listing. Coles has also served as Supervisory Board member of TME Pharma. Her experience across both public and private life science companies includes managing legal, compliance, intellectual property, corporate governance, board, and investor relations including activities around cross-border contracting, licensing, mergers and acquisitions, and business development. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations. During her six years at Sage, she drove people-centric strategies and initiatives that fostered the company’s culture and commercial growth and supported the eventual acquisition of Sage by Supernus Pharmaceuticals. Prior to Sage, Herbster held a global role at EMD Serono/Merck KGaA, managing Regulatory Affairs, Business Development & Alliance Management, as well as serving as the US Site Head for Research and Development. Prior to EMD Serono, she spent several years at Biogen serving in business partner roles of increasing scope and responsibility and her formative years within Human Resources at Johnson & Johnson. Her experience spans various facets of the industry, including mergers and acquisitions, divestitures, and the successful launch of consumer products, medical devices, and pharmaceuticals.Reported Earnings • Apr 01Full year 2025 earnings released: €1.90 loss per share (vs €3.08 loss in FY 2024)Full year 2025 results: €1.90 loss per share. Net loss: €354.1m (loss widened 92% from FY 2024). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.お知らせ • Jan 15+ 1 more updateInventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026Inventiva S.A. announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Nov 14Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 38,961,038 Price\Range: $3.85 Discount Per Security: $0.231お知らせ • Nov 13Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock)Breakeven Date Change • Oct 29No longer forecast to breakevenThe 7 analysts covering Inventiva no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.7m in 2027. New consensus forecast suggests the company will make a loss of €23.8m in 2027.お知らせ • Oct 16Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • Oct 03First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.お知らせ • Oct 02+ 1 more updateInventiva Announces CEO ChangesInventiva announced the appointment of Andrew Obenshain as Chief Executive Officer of the Company. He succeeds Frédéric Cren, the Company’s co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth transition and continuity in the Company’s strategic priorities. Mr. Obenshain was previously the CEO of bluebird bio, recently renamed Genetix Biotherapeutics, where he led the company’s transformation into a global commercial-stage gene therapy enterprise, successfully securing multiple regulatory approvals across major geographies. He brings more than 20 years of global leadership in drug development, regulatory strategy, and commercialization across the United States, Europe, and international markets. Prior to bluebird, Mr. Obenshain held senior leadership roles at Shire and Genzyme/Sanofi in France, with a focus on rare diseases and specialty therapeutics. He holds a B.A. in Genetics, Cell & Developmental Biology from Dartmouth College and an M.B.A. from Northwestern University’s Kellogg School of Management.Reported Earnings • Oct 01First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe.Breakeven Date Change • Oct 01Forecast to breakeven in 2027The 8 analysts covering Inventiva expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2026. The company is expected to make a profit of €15.7m in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule.業績と収益の成長予測XTRA:6IV - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028214-5180341012/31/2027118-863412001112/31/20265-146-47-741112/31/20257-354-105-105N/A9/30/202512-333-98-98N/A6/30/202517-311-91-91N/A3/31/202516-248-89-89N/A12/31/202414-184-86-86N/A9/30/202417-144-86-85N/A6/30/202419-104-85-85N/A3/31/202421-107-84-83N/A12/31/202323-110-82-82N/A9/30/202322-95-73-73N/A6/30/202322-80-64-64N/A3/31/202320-67-55-54N/A12/31/202218-54-45-45N/A9/30/202214-55-50-49N/A6/30/202210-56-55-54N/A3/31/202210-56-54-53N/A12/31/20219-50-48-48N/A9/30/20217-45-46-45N/A6/30/20216-41-44-43N/A3/31/20215-36-35-35N/A12/31/20205-34-31-31N/A9/30/20207-29-24-24N/A6/30/202010-25-17-17N/A3/31/202010-27-23-23N/A12/31/201911-30-29-28N/A9/30/20199-34N/A-33N/A6/30/20197-37N/A-38N/A3/31/20198-35N/A-35N/A12/31/20187-33N/A-34N/A9/30/20188-29N/A-27N/A6/30/20189-25N/A-21N/A3/31/20189-22N/A-19N/A12/31/201710-19N/A-17N/A9/30/201711-16N/A-18N/A6/30/201713-13N/A-19N/A3/31/201714-10N/A-17N/A12/31/201614-7N/A-15N/A9/30/201613-8N/A-14N/A6/30/201612-8N/A-13N/A3/31/201610-9N/A-13N/A12/31/20159-9N/A-14N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6IV今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 6IV今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 6IV今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 6IVの収益 ( 51.3% ) German市場 ( 6.6% ) よりも速いペースで成長すると予測されています。高い収益成長: 6IVの収益 ( 51.3% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6IVの 自己資本利益率 は、3年後には高くなると予測されています ( 33.8 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/16 21:23終値2026/07/14 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Inventiva S.A. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23 アナリスト機関Eliana MerleBarclaysEdward NashCanaccord GenuityEtzer DaroutGuggenheim Securities, LLC20 その他のアナリストを表示
Breakeven Date Change • Oct 29No longer forecast to breakevenThe 7 analysts covering Inventiva no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.7m in 2027. New consensus forecast suggests the company will make a loss of €23.8m in 2027.
Breakeven Date Change • Oct 01Forecast to breakeven in 2027The 8 analysts covering Inventiva expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2026. The company is expected to make a profit of €15.7m in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule.
お知らせ • Jun 04Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 27,272,727 Price\Range: $4.4 Discount Per Security: $0.264
お知らせ • Jun 03Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners LimitedInventiva S.A. entered into an agreement with funds and accounts managed by new investors BlackRock, Inc., and Claret Capital Partners Limited on June 1, 2026. The company will issue a first tranche for a maximum amount of €35 million consisting of senior secured convertible bonds, convertible into new ordinary shares, subject to satisfaction of certain closing conditions; a second tranche for a maximum amount of €40 million consisting of senior secured amortized bonds, subject to satisfaction of certain closing conditions; and a third tranche for a maximum amount of €55 million consisting of senior secured amortized bonds, available for the company to draw at its election until February 15, 2027. The company also has an optional additional tranche for a maximum amount of €20 million, subject to mutual consent, following the approval of the NDA for NATiV3. Pursuant to the terms of the subscription agreement, the lenders will receive warrants exercisable for up to €6.75 million worth of ordinary shares (or up to €12.35 million in the event of a shortfall event, as described below), expected to be granted concurrently with the drawdown of tranches A and B €2.75 million worth of ordinary shares are expected to be granted concurrently with the drawdown of tranche C.
お知らせ • May 26Inventiva S.A., Annual General Meeting, Jun 30, 2026Inventiva S.A., Annual General Meeting, Jun 30, 2026. Location: hotel villa m 24 30 boulevard pasteur, paris France
お知らせ • Apr 25Inventiva Announces Executives ChangesInventiva announced new members of its leadership team: Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These recruitments strengthen Inventiva’s leadership team as the Company prepares for the top-line data readout from the NATiV3 Phase 3 trial evaluating lanifibranor, expected in the fourth quarter of 2026. The new team members bring robust financial management, strong legal and governance oversight, and organizational expertise in building high-performing teams, positioning Inventiva to navigate its next phase of growth with confidence and discipline. Jean Volatier and Nathalie Harroy, who have respectively served as Chief Financial Officer and Head of Human Resources and have been with Inventiva since its inception, have played a key role in the Company’s development over the years and bring deep institutional knowledge. Jean Volatier will transition to the role of EVP Finance & Corporate Social Responsibility, where he will continue to support the Company on key strategic priorities. Nathalie Harroy will also remain with Inventiva, continuing to contribute her experience and expertise to the organization. The Company is pleased that both will remain part of Inventiva and continue to support its next phase of growth. Coles comes to Inventiva from Vivet Therapeutics, where she was head of Legal and Finance involved in all strategic and operational aspects of the business from the creation of the company through negotiations of an option to purchase deal with Pfizer. She previously was general counsel at Inventiva from 2012-2014 and again from 2019-2021, during its Nasdaq listing. Coles has also served as Supervisory Board member of TME Pharma. Her experience across both public and private life science companies includes managing legal, compliance, intellectual property, corporate governance, board, and investor relations including activities around cross-border contracting, licensing, mergers and acquisitions, and business development. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations. During her six years at Sage, she drove people-centric strategies and initiatives that fostered the company’s culture and commercial growth and supported the eventual acquisition of Sage by Supernus Pharmaceuticals. Prior to Sage, Herbster held a global role at EMD Serono/Merck KGaA, managing Regulatory Affairs, Business Development & Alliance Management, as well as serving as the US Site Head for Research and Development. Prior to EMD Serono, she spent several years at Biogen serving in business partner roles of increasing scope and responsibility and her formative years within Human Resources at Johnson & Johnson. Her experience spans various facets of the industry, including mergers and acquisitions, divestitures, and the successful launch of consumer products, medical devices, and pharmaceuticals.
Reported Earnings • Apr 01Full year 2025 earnings released: €1.90 loss per share (vs €3.08 loss in FY 2024)Full year 2025 results: €1.90 loss per share. Net loss: €354.1m (loss widened 92% from FY 2024). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
お知らせ • Jan 15+ 1 more updateInventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026Inventiva S.A. announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Nov 14Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 38,961,038 Price\Range: $3.85 Discount Per Security: $0.231
お知らせ • Nov 13Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock)
Breakeven Date Change • Oct 29No longer forecast to breakevenThe 7 analysts covering Inventiva no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.7m in 2027. New consensus forecast suggests the company will make a loss of €23.8m in 2027.
お知らせ • Oct 16Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • Oct 03First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
お知らせ • Oct 02+ 1 more updateInventiva Announces CEO ChangesInventiva announced the appointment of Andrew Obenshain as Chief Executive Officer of the Company. He succeeds Frédéric Cren, the Company’s co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth transition and continuity in the Company’s strategic priorities. Mr. Obenshain was previously the CEO of bluebird bio, recently renamed Genetix Biotherapeutics, where he led the company’s transformation into a global commercial-stage gene therapy enterprise, successfully securing multiple regulatory approvals across major geographies. He brings more than 20 years of global leadership in drug development, regulatory strategy, and commercialization across the United States, Europe, and international markets. Prior to bluebird, Mr. Obenshain held senior leadership roles at Shire and Genzyme/Sanofi in France, with a focus on rare diseases and specialty therapeutics. He holds a B.A. in Genetics, Cell & Developmental Biology from Dartmouth College and an M.B.A. from Northwestern University’s Kellogg School of Management.
Reported Earnings • Oct 01First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe.
Breakeven Date Change • Oct 01Forecast to breakeven in 2027The 8 analysts covering Inventiva expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2026. The company is expected to make a profit of €15.7m in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule.